To Demonstrate the Superiority of IMP (0.3% & 1% OPA-15406 Ointment)

Status Recruiting

Clinical Trial Summary

A multicenter, randomized, double-blind, vehicle-controlled, parallel group trial to demonstrate the superiority of 0.3% and 1% OPA-15406 ointment to vehicle in pediatric subjects with AD. This trial consists of the 0.3% OPA-15406 group, the 1% OPA-15406 group, and the vehicle group.

Clinical Trial Description

1. Screening period is defined as the interval between the day of obtaining informed consent and the day of the baseline visit (0-30 days). The investigator performs a screening examination after obtaining informed consent from the subject's legal guardian (and, if possible, after obtaining consent from the subject). 2. Assessment period (4 weeks double blind treatment period) is defined as the period between the day of baseline visit and the end of Week 4 visit (or the end of withdrawal visit). Subjects who meet the inclusion criteria and do not meet the exclusion criteria at the baseline visit will be assigned to receive 0.3% or 1% OPA-15406 ointment or comparator (vehicle [Placebo]). The allocated IMP will be administered to the treatment area from the day of baseline visit twice-daily for 4 weeks. After the baseline visit, examinations will be performed at Weeks 1, 2, and 4. If a subject discontinues the IMP administration between the day of baseline visit and the day of the Week 4 visit, a withdrawal visit will be performed for that subject. 3. Trial period(4 weeks double blind Treatment) The trial period for an individual subject is the period from the day of obtaining the written informed consent from the subject's legal guardian to the day of the Week 4 visit or withdrawal visit. For subjects who miss the Week 4 visit or withdrawal visit, the termination date, will be the date, as determined by the investigator, when the subject is withdrawn from the trial. The trial period does not include a follow-up period for AE. 4. 24 weeks, Open label, long term treatment period To be eligible for long term treatment, subjects must complete the randomized, double-blind treatment. Subjects must be judged by their investigators to have the potential for clinical benefit by longer-term exposure to OPA-15406, they can continue to receive 0.3% or 1% OPA-15406 open treatment for up to 24 weeks based on the inform consent of the subjects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05650320
Study type	Interventional
Source	Otsuka Beijing Research Institute
Contact	Baida Tang
Phone	010-85182966
Email	tangbaida@cn.otsuka.com
Status	Recruiting
Phase	Phase 3
Start date	February 17, 2023
Completion date	May 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03151148` - Targeted Microbiome Transplant in Atopic Dermatitis	Phase 1/Phase 2
Active, not recruiting	`NCT05456529` - Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis	Phase 3
Completed	`NCT04056130` - A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects	Phase 1
Recruiting	`NCT04173442` - Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
Completed	`NCT05372653` - A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis	Phase 3
Completed	`NCT03168113` - Atopic Dermatitis (AD) and Food Allergy	N/A
Terminated	`NCT03389893` - Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis	Phase 4
Recruiting	`NCT04541810` - A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Completed	`NCT02357940` - Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema	N/A
Recruiting	`NCT05667623` - To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD	Phase 3
Completed	`NCT01979016` - Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)	Phase 2
Withdrawn	`NCT04666675` - A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil	Phase 3
Active, not recruiting	`NCT05959083` - Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
No longer available	`NCT04159597` - Expanded Access to Upadacitinib

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms